ChemotherapyStressballNCT07072156
The Effect of Stress Ball Use on Stress, Anxiety, and Vital Signs in Patients Undergoing Chemotherapy for Breast Cancer
A study testing Stress ball in people with Chemotherapy and Breast Cancer Early Stage Breast Cancer (Stage 1-3), run by Ataturk University.
Trial summary
AIM This study aims to investigate the effects of stress ball use on stress, anxiety, and vital signs in patients receiving chemotherapy for breast cancer. METHOD This study will be conducted with 50 breast cancer patients receiving chemotherapy at the Outpatient Chemotherapy Unit of Rize Training and Research… Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Chemotherapy, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- What is being tested?
- Stress ball
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2025to 1 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Stage 2A-2B breast cancer
- Receiving neoadjuvant chemotherapy
- On a chemotherapy protocol administered every 21 days
- Receiving second or subsequent chemotherapy cycle
- No migraine, vertigo, active nausea, vomiting, or headache
- No history of seizures
Show all 11Show fewer
- No primary or metastatic brain cancer
- No visual, hearing, or cognitive impairment
- Age 18 or older
- No communication barriers
- Voluntary participation
Who cannot join
- Cancer types other than breast cancer
- Unilateral or bilateral mastectomy
- Any condition preventing hand use (e.g., pain, fracture, open wound)
- IV access in both arms
- Psychiatric diagnosis
- Diagnosed anxiety disorder or current anti-anxiety medication use
About this study
AIM This study aims to investigate the effects of stress ball use on stress, anxiety, and vital signs in patients receiving chemotherapy for breast cancer.
METHOD This study will be conducted with 50 breast cancer patients receiving chemotherapy at the Outpatient Chemotherapy Unit of Rize Training and Research Hospital, using a randomized controlled experimental design. Simple randomization will be used for group assignment. Data will be collected using a Breast Cancer Patient Information Form, Distress Thermometer, and State Anxiety Inventory. It is planned that data will be collected both before and after the chemotherapy session.
Read more
ORIGINALITY / SCIENTIFIC CONTRIBUTION To date, no study has been found in the literature evaluating the effects of stress balls on stress, anxiety, and vital signs in breast cancer patients undergoing chemotherapy. Therefore, this project is considered original and is expected to contribute to both national and international scientific literature. If successful, the project will provide evidence for a new non-pharmacological intervention that is easy to use during chemotherapy sessions and can help improve patients' stress, anxiety, and vital signs. Patients may experience more comfort and better treatment compliance during chemotherapy.
EXPECTED OUTCOMES It is expected that the use of a stress ball will have a positive effect on reducing stress and anxiety levels and improving vital signs in breast cancer patients receiving chemotherapy.
Read the detailed description
METHOD This study is planned as a single-blind, randomized controlled experimental design. It will be conducted with breast cancer patients receiving chemotherapy at Rize Training and Research Hospital's Chemotherapy Unit.
POPULATION AND SAMPLE The study population consists of breast cancer patients receiving chemotherapy at the aforementioned hospital during the research period. Since no previous study has evaluated the effect of stress ball use on stress, anxiety, and vital signs in this population, the sample size was calculated using Cohen's large effect size (d = 0.80) via the G*Power 3.1.9.7 program. With α = 0.05 and power = 80%, the minimum required sample size was found to be 42. To account for possible data loss, 20% more participants will be included. Therefore, 25 patients will be assigned to each group, totaling 50 participants. The study will be reported in accordance with the CONSORT guidelines for randomized controlled trials.
INCLUSION CRITERIA Stage 2A-2B breast cancer
Receiving neoadjuvant chemotherapy
On a chemotherapy protocol administered every 21 days
Receiving second or subsequent chemotherapy cycle
No migraine, vertigo, active nausea, vomiting, or headache
No history of seizures
No primary or metastatic brain cancer
No visual, hearing, or cognitive impairment
Age 18 or older
No communication barriers
Voluntary participation
EXCLUSION CRITERIA Cancer types other than breast cancer
Unilateral or bilateral mastectomy
Any condition preventing hand use (e.g., pain, fracture, open wound)
IV access in both arms
Psychiatric diagnosis
Diagnosed anxiety disorder or current anti-anxiety medication use
WITHDRAWAL CRITERIA Patient requests to withdraw
Change in institution or city
Any illness developed during the intervention
Patient's death
RANDOMIZATION Patients meeting inclusion criteria and consenting to participate will be randomized into two groups using simple randomization via Excel's RAND function. Patients assigned even numbers will be placed in the stress ball group, and those with odd numbers in the control group.
BLINDING To minimize bias, both the researcher and the statistician will be blinded. Randomization will be performed by a researcher not involved in data collection. While the researcher administering the intervention will be aware of group allocation, data entry into SPSS will label groups as "Group 1" and "Group 2" without revealing the group type to the statistician.
IMPLEMENTATION OF THE RESEARCH Fifty eligible and consenting patients will be selected. After collecting pre-test data (prior to chemotherapy), patients in the intervention group will receive a stress ball following premedication. They will be instructed to focus on and squeeze the ball for 15-20 minutes during chemotherapy. The control group will continue with routine treatment and care. Post-test data will be collected after the chemotherapy session.
STRESS BALL DETAILS The stress ball is made of high-quality silicone, regaining its shape after squeezing. The ball used in this study is medium firmness (blue), elliptical, and 6 cm in diameter, suitable for adult use. Patients will be taught how to use the stress ball, including coordinated breathing techniques (inhale when squeezing, exhale when releasing). Stress balls will be given to intervention group patients to keep. Control group patients may request a ball after the study concludes.
DATA COLLECTION TOOLS Data will be collected using the Breast Cancer Patient Information Form, Distress Thermometer, and State Anxiety Inventory. Pre- and post-chemotherapy session measurements are planned.
Breast Cancer Patient Information Form:
Includes 11 items regarding age, marital status, education, economic status, employment, smoking and alcohol use, disease duration and stage, presence of chronic illness, and family history of cancer.
Distress Thermometer (DT):
Assess psychosocial distress in cancer patients. It uses a scale from 0 (no distress) to 10 (extreme distress). Scores ≥4 are considered clinically significant. Turkish validity and reliability studies were conducted by Özalp et al.
State Anxiety Inventory (STAI):
This study uses the state anxiety subscale to assess anxiety triggered by specific situations. It consists of 20 items scored on a 4-point Likert scale, where total scores range from 20 to 80. Higher scores indicate greater anxiety.
DATA ANALYSIS Data will be analyzed using SPSS version 26. Descriptive statistics (number, percentage, mean, standard deviation) will be used. For within-group comparisons: paired samples t-test (normal distribution) or Wilcoxon test (non-normal). For between-group comparisons: independent samples t-test (normal) or Mann-Whitney U test (non-normal). A p-value of <0.05 will be considered statistically significant.
STUDY FLOWCHART SUMMARY Stress Ball Group
First Interview: Consent is obtained; group allocation is done.
Pre-test: Patient information form, DT, STAI, and vital signs are assessed.
Intervention: Stress ball use for 15-20 minutes during chemotherapy.
Post-test: Same measurements are repeated.
Control Group
Same steps as above, but no intervention; only routine treatment is provided.
LIMITATIONS This study is limited to 50 breast cancer patients receiving chemotherapy at the outpatient chemotherapy unit of Rize Training and Research Hospital.
BUDGET JUSTIFICATION 25 stress balls for the intervention group
5 spare stress balls
10 stress balls for the control group (to be given post-study upon request)
RESEARCH FACILITIES Access to 50 breast cancer patients at Rize Training and Research Hospital's Outpatient Chemotherapy Unit
Researcher computers provided by affiliated universities
Hospital devices (blood pressure monitor and pulse oximeter) for vital sign measurements
Stress balls to be purchased with project funds
- Being tested
- Stress ball
- Keywords
- Stress Ball, breast cancer, stress, Anxiety, Vital Signs
- Medical subject headings
- Breast Neoplasms, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stress ballOther
First Interview: Consent is obtained; group allocation is done.
Pre-test: Patient information form, DT, STAI, and vital signs are assessed.
Intervention: Stress ball use for 15-20 minutes during chemotherapy.
Post-test: Same measurements are repeated.
| Study group | Role | What they receive |
|---|---|---|
| Stress ball group | Experimental | Stress Ball Group
First Interview: Consent is obtained; group allocation is done.
Pre-test: Patient information form, DT, STAI, and vital signs are assessed.
Intervention: Stress ball use for 15-20 minutes during chemotherapy.
Post-test: Same measurements are repeated. Receives: Other: Stress ball |
| Control Group | No intervention | Same steps as above, but no intervention; only routine treatment is provided. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Distress Thermometer (DT):
It assesses the state anxiety an individual feels due to the stressful situation they are in, their predisposition to this anxiety, and the trait anxiety that generally characterizes the situations they find themselves in as stressful. The total score on the scale ranges from 20 to 80, with higher scores indicating higher anxiety levels and lower scores indicating lower anxiety levels.
Measured: 1 per month for 3 months
Secondary outcomes (1)
State Anxiety Inventory (STAI):
It assesses the state anxiety an individual feels due to the stressful situation they are in, their predisposition to this anxiety, and the trait anxiety that generally characterizes the situations they find themselves in as stressful. The total score on the scale ranges from 20 to 80, with higher scores indicating higher anxiety levels and lower scores indicating lower anxiety levels.
Measured: 1 per month for 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2025
- Study start1 Aug 2025 (estimated)
- Primary completion1 Nov 2025 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ChemotherapyStudies of the same condition, open and under way.
- More trials run by Ataturk UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Stress Ball Group First Interview: Consent is obtained; group allocation is done. Pre-test: Patient information form, DT, STAI, and vital signs are assessed. Intervention: Stress ball use for 15-20 minutes during chemotherapy. Post-test: Same measurements are repeated.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ataturk University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bedriye Cansu DEMİRKIRAN, Ataturk Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07072156
- Sponsor's protocol ID
- Stresballbreastca
- Acronym
- Stressball
- Status last verified
- Jul 2025
- First submitted
- 7 Jul 2025
- Last updated
- 18 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 18 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Stress Ball Use on Stress, Anxiety, and Vital Signs in Patients Undergoing Chemotherapy for Breast Cancer
- ClinicalTrials.gov ID
- NCT07072156
- Acronym / sponsor ID
- Stressball / Stresballbreastca
- Keywords
- Stress Ball, breast cancer, stress, Anxiety, Vital Signs
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Ataturk UniversityUniversity, hospital or other
- Study start
- 1 Aug 2025 (estimated)
- Primary completion
- 1 Nov 2025 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 18 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
AIM This study aims to investigate the effects of stress ball use on stress, anxiety, and vital signs in patients receiving chemotherapy for breast cancer.
METHOD This study will be conducted with 50 breast cancer patients receiving chemotherapy at the Outpatient Chemotherapy Unit of Rize Training and Research Hospital, using a randomized controlled experimental design. Simple randomization will be used for group assignment. Data will be collected using a Breast Cancer Patient Information Form, Distress Thermometer, and State Anxiety Inventory. It is planned that data will be collected both before and after the chemotherapy session.
ORIGINALITY / SCIENTIFIC CONTRIBUTION To date, no study has been found in the literature evaluating the effects of stress balls on stress, anxiety, and vital signs in breast cancer patients undergoing chemotherapy. Therefore, this project is considered original and is expected to contribute to both national and international scientific literature. If successful, the project will provide evidence for a new non-pharmacological intervention that is easy to use during chemotherapy sessions and can help improve patients' stress, anxiety, and vital signs. Patients may experience more comfort and better treatment compliance during chemotherapy.
EXPECTED OUTCOMES It is expected that the use of a stress ball will have a positive effect on reducing stress and anxiety levels and improving vital signs in breast cancer patients receiving chemotherapy.
Detailed description
METHOD This study is planned as a single-blind, randomized controlled experimental design. It will be conducted with breast cancer patients receiving chemotherapy at Rize Training and Research Hospital's Chemotherapy Unit.
POPULATION AND SAMPLE The study population consists of breast cancer patients receiving chemotherapy at the aforementioned hospital during the research period. Since no previous study has evaluated the effect of stress ball use on stress, anxiety, and vital signs in this population, the sample size was calculated using Cohen's large effect size (d = 0.80) via the G*Power 3.1.9.7 program. With α = 0.05 and power = 80%, the minimum required sample size was found to be 42. To account for possible data loss, 20% more participants will be included. Therefore, 25 patients will be assigned to each group, totaling 50 participants. The study will be reported in accordance with the CONSORT guidelines for randomized controlled trials.
INCLUSION CRITERIA Stage 2A-2B breast cancer
Receiving neoadjuvant chemotherapy
On a chemotherapy protocol administered every 21 days
Receiving second or subsequent chemotherapy cycle
No migraine, vertigo, active nausea, vomiting, or headache
No history of seizures
No primary or metastatic brain cancer
No visual, hearing, or cognitive impairment
Age 18 or older
No communication barriers
Voluntary participation
EXCLUSION CRITERIA Cancer types other than breast cancer
Unilateral or bilateral mastectomy
Any condition preventing hand use (e.g., pain, fracture, open wound)
IV access in both arms
Psychiatric diagnosis
Diagnosed anxiety disorder or current anti-anxiety medication use
WITHDRAWAL CRITERIA Patient requests to withdraw
Change in institution or city
Any illness developed during the intervention
Patient's death
RANDOMIZATION Patients meeting inclusion criteria and consenting to participate will be randomized into two groups using simple randomization via Excel's RAND function. Patients assigned even numbers will be placed in the stress ball group, and those with odd numbers in the control group.
BLINDING To minimize bias, both the researcher and the statistician will be blinded. Randomization will be performed by a researcher not involved in data collection. While the researcher administering the intervention will be aware of group allocation, data entry into SPSS will label groups as "Group 1" and "Group 2" without revealing the group type to the statistician.
IMPLEMENTATION OF THE RESEARCH Fifty eligible and consenting patients will be selected. After collecting pre-test data (prior to chemotherapy), patients in the intervention group will receive a stress ball following premedication. They will be instructed to focus on and squeeze the ball for 15-20 minutes during chemotherapy. The control group will continue with routine treatment and care. Post-test data will be collected after the chemotherapy session.
STRESS BALL DETAILS The stress ball is made of high-quality silicone, regaining its shape after squeezing. The ball used in this study is medium firmness (blue), elliptical, and 6 cm in diameter, suitable for adult use. Patients will be taught how to use the stress ball, including coordinated breathing techniques (inhale when squeezing, exhale when releasing). Stress balls will be given to intervention group patients to keep. Control group patients may request a ball after the study concludes.
DATA COLLECTION TOOLS Data will be collected using the Breast Cancer Patient Information Form, Distress Thermometer, and State Anxiety Inventory. Pre- and post-chemotherapy session measurements are planned.
Breast Cancer Patient Information Form:
Includes 11 items regarding age, marital status, education, economic status, employment, smoking and alcohol use, disease duration and stage, presence of chronic illness, and family history of cancer.
Distress Thermometer (DT):
Assess psychosocial distress in cancer patients. It uses a scale from 0 (no distress) to 10 (extreme distress). Scores ≥4 are considered clinically significant. Turkish validity and reliability studies were conducted by Özalp et al.
State Anxiety Inventory (STAI):
This study uses the state anxiety subscale to assess anxiety triggered by specific situations. It consists of 20 items scored on a 4-point Likert scale, where total scores range from 20 to 80. Higher scores indicate greater anxiety.
DATA ANALYSIS Data will be analyzed using SPSS version 26. Descriptive statistics (number, percentage, mean, standard deviation) will be used. For within-group comparisons: paired samples t-test (normal distribution) or Wilcoxon test (non-normal). For between-group comparisons: independent samples t-test (normal) or Mann-Whitney U test (non-normal). A p-value of <0.05 will be considered statistically significant.
STUDY FLOWCHART SUMMARY Stress Ball Group
First Interview: Consent is obtained; group allocation is done.
Pre-test: Patient information form, DT, STAI, and vital signs are assessed.
Intervention: Stress ball use for 15-20 minutes during chemotherapy.
Post-test: Same measurements are repeated.
Control Group
Same steps as above, but no intervention; only routine treatment is provided.
LIMITATIONS This study is limited to 50 breast cancer patients receiving chemotherapy at the outpatient chemotherapy unit of Rize Training and Research Hospital.
BUDGET JUSTIFICATION 25 stress balls for the intervention group
5 spare stress balls
10 stress balls for the control group (to be given post-study upon request)
RESEARCH FACILITIES Access to 50 breast cancer patients at Rize Training and Research Hospital's Outpatient Chemotherapy Unit
Researcher computers provided by affiliated universities
Hospital devices (blood pressure monitor and pulse oximeter) for vital sign measurements
Stress balls to be purchased with project funds
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Stress Ball Group First Interview: Consent is obtained; group allocation is done. Pre-test: Patient information form, DT, STAI, and vital signs are assessed. Intervention: Stress ball use for 15-20 minutes during chemotherapy. Post-test: Same measurements are repeated.
| Arm | Type | Receives |
|---|---|---|
| Stress ball group | Experimental | Other: Stress ballStress Ball Group First Interview: Consent is obtained; group allocation is done. Pre-test: Patient information form, DT, STAI, and vital signs are assessed. Intervention: Stress ball use for 15-20 minutes during chemotherapy. Post-test: Same measurements are repeated. |
| Control Group | No intervention | –Same steps as above, but no intervention; only routine treatment is provided. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Stage 2A-2B breast cancer
- Receiving neoadjuvant chemotherapy
- On a chemotherapy protocol administered every 21 days
- Receiving second or subsequent chemotherapy cycle
- No migraine, vertigo, active nausea, vomiting, or headache
Key exclusion criteria (6 listed)
- Cancer types other than breast cancer
- Unilateral or bilateral mastectomy
- Any condition preventing hand use (e.g., pain, fracture, open wound)
- IV access in both arms
- Psychiatric diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Stress ballFirst Interview: Consent is obtained; group allocation is done. Pre-test: Patient information form, DT, STAI, and vital signs are assessed. Intervention: Stress ball use for 15-20 minutes during chemotherapy. Post-test: Same measurements are repeated. | Other | Stress ball group |
Primary outcome
Distress Thermometer (DT):
Time frame: 1 per month for 3 months
It assesses the state anxiety an individual feels due to the stressful situation they are in, their predisposition to this anxiety, and the trait anxiety that generally characterizes the situations they find themselves in as stressful. The total score on the scale ranges from 20 to 80, with higher scores indicating higher anxiety levels and lower scores indicating lower anxiety levels.
1 secondary outcome
State Anxiety Inventory (STAI):
Time frame: 1 per month for 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jul 2025.
- Individual participant dataSharing planned: Yes
Related trials for Chemotherapy
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma
Thrombotic Thrombocytopenic Purpura (TTP)
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Stress ball in people with Chemotherapy and Breast Cancer Early Stage Breast Cancer (Stage 1-3), run by Ataturk University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Distress Thermometer (DT): (time frame: 1 per month for 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jul 2025.